Parexel and Palantir Technologies, a leading builder of Artificial Intelligence (AI) systems, today announced a multi-year strategic partnership to leverage AI to help enhance and accelerate the delivery of safe and effective clinical trials for the world’s biopharmaceutical customers. Under the collaboration, Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform (AIP) to further power its clinical data platform with a focus on driving clinical trial efficiency while maintaining the highest level of safety and regulatory rigor. Parexel is the first CRO working with Palantir in this capacity. Click through highlights from the announcement below or read the full release: https://lnkd.in/dyZrdiYS #ArtificialIntelligence #AI
About us
Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, our team of more than 21,000 global professionals collaborates with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind, increasing access and participation to make clinical research a care option for anyone, anywhere. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas, while our innovation ecosystem offers the best solutions to make every phase of the clinical trial process more efficient. With the people, insight and focus on operational excellence, we work With HeartTM every day to treat patients with dignity and continuously learn from their experiences, so every trial makes a difference. For more information, visit parexel.com. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove any comments that do not adhere to our guidelines as well as report users who violate the rules of our page.
- Website
-
http://www.parexel.com
External link for Parexel
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Durham, North Carolina
- Type
- Privately Held
- Specialties
- Regulatory and product development consulting, early phase clinical research, phase II-III clinical research, late phase clinical research, eClinical solutions, patient and site recruitment, medical device consulting, clinical research organization, pharmacovigilance, biotechnology, biotech, and market access
Locations
-
Primary
Get directions
2520 Meridian Pkwy
Durham, North Carolina 27713, US
Employees at Parexel
Updates
-
As we embrace the exciting future ahead for Parexel, we’re excited to unveil our new brand campaign featuring our world-class experts, like our colleague, project director Mika Pollack. This campaign spotlights our team’s unique ability to fall in love with challenges, uncover insights, and speed life-changing medicines to those who need them the most. Novel insights to shape your clinical development on Parexel.com/insights.
-
Last week, Parexel leaders and customers gathered at our Early Phase Clinical Unit (EPCU) in Berlin to tour the recently updated space and learn about the role of our EPCUs in clinical trials. Attendees had the opportunity to network before hearing updates from Parexel’s Peyton Howell, Oliver Fuhrmann and Matthias Lenk. The guided tour provided a walkthrough of the facilities and introductions to various team members, offering insights into their contributions to early phase trials. Check out photos from the event below! 📷
-
-
🎉 Significant #AI milestone reached in clinical research! 💊 The FDA has accepted Deliberate AI’s depression and anxiety model, AI-COA™, or AI-based clinical outcome assessment, for regulatory evaluation. The tool assesses multimodal behavioral and physiological indicators of depression, as opposed to subjective questionnaires we’ve primarily relied on to this point. In this edition of our New Medicines, Novel Insights newsletter, Parexel’s Chief Data Officer Stephen Pyke sits down with clinical research experts Stacy Hurt 🌻 and Andreas Lysandropoulos MD, PhD to discuss the challenges and dazzling possibilities applications based on AI have to advance novel medicine, improve development efficiencies and continually enhance patient outcomes. Learn about the exciting doors AI applications are opening in neuroscience trials and clinical research as revolutionary efficiencies are being reached in less time, with increased accuracy. Like and subscribe to stay updated with more #NovelInsights from our bi-weekly newsletter! #ArtificialIntelligence #Neuroscience #Regulatory #PatientsFirst
AI Milestones: FDA’s ISTAND program accepts AI-based assessment tool for depression
Parexel on LinkedIn
-
It’s that time of the year again, and our team is thrilled to be returning to the World Orphan Drug Congress USA 2024 in Boston! Rachel Smith, Head of Rare Disease at Parexel, leads an esteemed panel, including Peter Marks from the FDA, Mark Trusheim from Tufts Medical Center, Jamie Sullivan from EveryLife Foundation for Rare Diseases, and Kinnari Patel, PharmD, MBA from Rocket Pharmaceuticals, exploring the latest regulatory challenges and opportunities in accelerating rare disease treatments for patients in need. Our Medical Director, Renata C. Gallagher, MD, PhD, will speak on the challenges of genotype interpretation and phenotype variation in rare diseases. Additionally, Kim MacDonnell, BScN, MSc, RN, CGC will host a roundtable on AI-generated patient stories, how to identify them, and the benefits and threats they pose. Learn more about our participation or schedule a meeting with us at the event here: https://lnkd.in/gAiKdDe9 #WODC #WODC24 #WorldOrphanUSA #raredisease #orphandrugs
-
🌎 This Earth Day, we renew our pledge to diminish our environmental impact while enhancing our operational efficiency. 🌏 As a company at the forefront of advancing global health, we recognize our responsibility to mitigate the health risks associated with climate change. From driving forward decentralized clinical trials to reducing our resource usage and shrinking our physical office space, we're committed to implementing innovative solutions that contribute to a healthier planet. Explore our latest Environmental, Social and Governance (ESG) report to learn about our objectives for climate action, energy consumption and worldwide green initiatives. Also, keep an eye out for our 2023 report! We're eager to share our progress in achieving our climate objectives. https://lnkd.in/eGYqMXjS #EarthDay #ESG
-
As part of Applied Clinical Trials Magazine's deep dive into the impact of AI, Stephen Pyke weighed in on why data sharing is critical for propelling forward applications like ChatGPT and other generative AI models. Hear from Stephen on the “fine tuning” that’s still required to advance these applications and why collaboration is key to delivering on the promise of AI: https://lnkd.in/eMP-bZXP #AIinClinicalTrials #ResponsibleAI
-
The neuroscience regulatory landscape is changing quickly, with more progressive FDA decision-making leading to accelerated approvals. However, new drugs won’t reach patients unless supported by data packages that satisfy health technology assessment (HTA) agencies and payers. In this article, written by Aleksandra (Ola) Lubojemska and Andreas Lysandropoulos MD, PhD, gain valuable insights on differentiating new drugs in crowded markets and the anticipatory steps to take, ensuring optimal go-to-market outcomes. Read more for expert advice on navigating the evolving neuroscience landscape and maximizing market success: https://lnkd.in/gehi-EyG #Neuroscience #MarketAccess #Regulatory #ParexelBiotech
-
Ukraine has faced significant challenges due to the ongoing war but Parexel has remained committed to supporting our clinical operations throughout the crisis. Our Kyiv office never stopped working or delivering for patients despite the challenges. Two years later, Parexel is involved in more than a dozen clinical studies in Ukraine across a range of therapeutic areas and is helping the country reclaim its position as a leading biotech and research hub. In this article from PharmaVoice, Deb Garand Tatton and Aleksei Zhmuro share how the company prioritized patient and staff safety and overcame logistical barriers to ensure research continuity and patient access to trials. Read their firsthand insights: https://lnkd.in/eEfsxsAp
Ukraine was pharma’s ‘darling’ of clinical trials. As war drags on, will the industry come back?
pharmavoice.com
-
What an incredible week at #AAN2024! Collaborating with such great people and brilliant professionals is always a privilege. The opportunity and innovation in neuroscience is inspiring to see as we strive to improve treatment options for patients! Andreas Lysandropoulos MD, PhD, SVP and Global Therapeutic Area Head - Neuroscience at Parexel, shared his insights on patient recruitment and retention and held a poster presentation on current neuroscience clinical research trends, highlighting the increasing acceptance of RWE to inform regulatory decision-making in rare and progressive neuromuscular disease submissions. If you’re interested in learning more, join Andreas for a webinar next week examining development challenges in Alzheimer’s Disease and Multiple Sclerosis and the shared lessons from each that can propel novel approaches to more effective trial outcomes. 🗓️ Date: 04/23/24 ⏰ Time: 11:00 am EDT 🌐 Register: https://lnkd.in/g_fb6E2u #AANAM #Neuroscience #Neurology #Alzheimers #MultipleSclerosis
-